Pablo J. Cagnoni, M.D., serves as the President of Research and Development at INCYTE CORP, a leading biopharmaceutical company focused on developing and commercializing innovative therapies. Dr. Cagnoni is a seasoned executive with extensive experience in the pharmaceutical industry, particularly in oncology and hematology. Before joining INCYTE, he held the position of President of U.S. Oncology at Baxalta, where he was instrumental in driving the growth and development of their oncology portfolio. Prior to Baxalta, Dr. Cagnoni served as Senior Vice President and Chief Medical Officer at Onyx Pharmaceuticals, where he played a key role in the successful development and launch of several groundbreaking cancer treatments. At INCYTE, Dr. Cagnoni leads a team of dedicated scientists and researchers in the discovery and development of novel therapeutics across various therapeutic areas, including oncology, inflammation, and autoimmunity. Under his leadership, INCYTE has made significant strides in advancing its pipeline of innovative medicines, with several promising drug candidates currently in clinical trials. Dr. Cagnoni's strategic vision and commitment to scientific excellence have been instrumental in positioning INCYTE as a leader in the biopharmaceutical industry. His expertise in drug development, coupled with his passion for improving patient outcomes, has earned him a reputation as a respected thought leader and innovator in the field of medicine. In addition to his professional accomplishments, Dr. Cagnoni is a board-certified hematologist and oncologist who has published numerous peer-reviewed articles and has been an invited speaker at various scientific conferences. He received his medical degree from the University of Buenos Aires School of Medicine and completed his residency and fellowship training at the University of Colorado Health Sciences Center. Dr. Cagnoni's dedication to advancing medical science and his unwavering commitment to improving the lives of patients make him an invaluable asset to INCYTE and the broader healthcare community.